(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
RAPT Therapeutics (RAPT) said Monday results from a phase 1b clinical trial of its RPT193 oral treatment in patients with moderate-to-severe atopic...
RAPT Therapeutics (RAPT) has an average rating of outperform and price targets ranging from $52 to $72, according to analysts polled by Capital IQ. (MT...
| Address | 561 Eccles Avenue South San Francisco, California 94080 |
| Phone | +1.650.489.9000 |
| Number of Employees | 64 |
| Recent SEC Filing | 05/12/2022 4 |
| President, Chief Executive Officer & Director | Brian Russell Wong |
| Chief Financial Officer & Secretary | Rodney K. B. Young |
| Chief Medical Officer | William Ho |
| Chief Scientific Officer | Dirk G. Brockstedt |
| Price Open | $14.25 |
| Previous Close | $13.43 |
| 52 Week Range | $9.86 - 43.26 |
| Market Capitalization | $398.1 M |
| Shares Outstanding | 29.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/10/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.53 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -1,814.95% |
| Return on Equity | -39.69% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
